Biotech Stock Picker

Delcath Systems to Take on Onyx Pharma's Nexavar

It was pointed out to me that there is a misspelling of PFE's drug referenced. The correct spelling is 'Sutent', if you notice the link in point 2 the spelling is correct, but in the article I, for whatever reason, threw in an extra 't'. Sorry for that. And please do not let that get in the way of the analysis.

Also it was mentioned to me that Sutent does not compete with Nexavar in liver cancer as only Nexavar is approved for this indication. Yes this is true. But please understand the main point was to tie in Pfizer because of the use doxorubicin, not necessarily Sutent.

Also I had a comment that Sutent has not shown in early trials as much promise for liver cancer as hoped. This is besides the point. In fact, according to this article - www.thehindubusinessli... - Pfizer is planning a phase III trail for liver cancer in Asia. I cannot confirm but I believe this will be testing Sutent (anyone know different please post). But even if true (that Sutent dies not work in liver cancer) this supports my analysis that the use of DOXO with Delcath PHP may draw PFE attention.

Thanks for the feedback.